The dynamic regulation of protein tyrosine phosphorylation is a critical feature of intercellular communication and is regulated by the actions of kinases and phosphatases. The receptorlinked protein tyrosine phosphatases (RPTPs) are key signaling molecules that possess an extracellular domain and intracellular phosphatase domains. Most human RPTPs have tandem intracellular tyrosine phosphatase domains: a catalytically active membrane proximal (D1) domain; and a membrane distal (D2) inactive "pseudophosphatase" domain. The receptor PTPRU plays a role in development, multiple cancers and has been implicated in the dephosphorylation of cell adhesion proteins. However, PTPRU has a non-canonical D1 domain containing several sequence variations in key catalytic loops that suggest it may function using a mechanism distinct from related RPTPs. Here, we demonstrate through biochemical and structural studies that PTPRU is unique amongst the RPTPs in possessing two pseudophosphatase domains. We show that PTPRU-D1 displays no detectable catalytic activity against a range of phosphorylated substrates and determine that this is due to substantial disorder in the substrate-binding pocket as well as rearrangement of the catalytic loop such that the active site cysteine is occluded. We also show that this cysteine can form an intramolecular disulfide bond with a vicinal "backdoor" cysteine. Further, we demonstrate that the PTPRU D2 domain can recruit substrates of related RPTPs suggesting that this pseudophosphatase functions by competing with active phosphatases for the binding of substrates involved in cell adhesion. Therefore, PTPRU is a bona-fide pseudophosphatase and its functional role in cell signaling is via a non-catalytic mechanism.
conserved in classical PTPs (Fig. 3Ai) , but in PTPRU-D1 this loop is arranged such that the sidechain of T1089 is in close proximity to the active site cysteine (3. 0 Å between T1089 OG1 and C1085 SG atoms, Fig. 3Aii ). Although the majority of the surrounding active site residues are maintained in the canonical conformation, this new loop orientation blocks the catalytic cysteine and would directly interfere with pTyr binding (Fig. 3Aiii) . A threonine at this position in the PTP loop is unique to the PTPRU-D1 domain (SI Appendix, Fig. S1 ). To probe the importance of this residue for catalysis we created a PTPRU-D1 T1089A mutant and the reciprocal PTPRK-D1 A1093T and tested these in dephosphorylation assays. Introduction of a threonine to the active site was not sufficient to inactivate PTPRK-D1 ( Fig. 3B) . Further, removal of the active site threonine was not sufficient to reactivate PTPRU-D1 and a double mutant E1053D and T1089A also remained inactive (Fig. 3B) . The combined effect of a disordered pTyr recognition loop and reorientation of the catalytic PTP loop is the loss of key structural features normally required for binding and processing of phosphorylated substrates ( Fig. 3C) .
In PTP1B a secondary pTyr binding site was identified by binding of a peptide containing tandem pTyr residues (38) (PDB ID: 1G1H). This secondary site is proximal to the active site and pTyr binding involves two arginine residues (R24 and R254 in PTP1B). One of the arginine residues, R254, is completely conserved in all D1 sequences except PTPRU where it is uniquely a cysteine (C1121) (7) . The loop containing this cysteine in PTPRU-D1 (C1121 to M1127) is poorly ordered and the difficulty of building a single, reliable conformation in the electron density suggests it may adopt multiple conformations. The importance of a cysteine residue in this secondary binding site, in a position resembling that of an active site cysteine, remains unclear.
Structure of oxidized PTPRU-D1
In an attempt to determine if substrate binding might induce folding of the pTyr recognition loop or rearrangement of the catalytic PTP loop, we soaked PTPRU-D1 crystals with several potential ligands including PO4, pTyr and PNP. In none of the datasets collected for these crystal soaks was there any evidence of ligand binding in the active site or any induced folding of the pTyr recognition loop. However, these crystals, collected 4 weeks after the initial datasets, had clearly undergone oxidation resulting in the formation of a disulfide bridge between the catalytic C1085 and the vicinal "backdoor" cysteine, C998 (Fig. 4Ai) . This alternate conformation involving disulfide bond formation with nearby cysteines has been observed for several other related phosphatases ( Fig. 4Aii) (39) (40) (41) (42) . This disulfide formation upon oxidation has been proposed to protect the catalytic cysteine from oxidative damage and/or function as a redox-sensitive mechanism for reversible PTP inactivation (39-42). The formation of this disulfide in PTPRU-D1 destabilizes the conformation of adjacent residues in the PTP-loop as there is no clear density in which to model S1086-G1088 (Fig. 4B) . The nearby loop (C1121-M1127) previously implicated as a secondary pTyr binding site is also further destabilized in this oxidized structure as evidenced by a lack of electron density for this region. Non-reducing SDS-PAGE of PTPRU-D1 recombinant protein in the presence of hydrogen peroxide results in a mobility shift consistent with disulfide formation in solution, which is completely reversed under reducing conditions (Fig. 4C) . While PTPRK-D1 conserves this "backdoor" cysteine, it does not undergo detectable disulfide formation under the same conditions ( Fig. 4C) . Thus, the catalytic cysteine of PTPRU-D1 can undergo reversible oxidation, involving intramolecular disulfide formation, identifying this domain as a redox-sensitive pseudophosphatase.
PTPRU interacts with PTPRK substrates
To understand the role of PTPRU in signaling, we exploited our previous observation based on domain-swapping intracellular domain (ICD) chimeras showing that the PTPRK, but not PTPRM, D2 domain was critical for recognition of Afadin (3), a reported PTPRU interactor (29). Although we were unable to purify full PTPRU-ICD (D1+D2), we were able to generate an in vivo biotinylated chimeric ICD consisting of the active PTPRK-D1 and the PTPRU-D2 domain ( Fig. 5A; SI Appendix, Fig. S4A and S4B) . We then tested the ability of chimeric proteins to bind and dephosphorylate PTPRK substrates. To probe protein-substrate interactions, we conjugated biotinylated chimeric proteins to streptavidin beads for in vitro pulldowns from pervanadate-treated cell lysates followed by immunoblotting. While the PTPRK and PTPRM substrate p120-Catenin (p120 Cat ) (3) could interact with all chimeras regardless of D2 domain, we found that unlike PTPRM-D2, the PTPRU-D2 domain is sufficient for binding to Afadin (Fig. 5B) . Consistent with this interaction data, immunoprecipitation of tyrosine phosphorylated proteins from dephosphorylation assays confirmed the PTPRU-D2 domain as being sufficient to recruit Afadin for dephosphorylation by the active PTPRK-D1 domain (dephosphorylated proteins are depleted in pTyr IPs and/or enriched in supernatants; Fig.   5C ). Our data suggest that in cells PTPRU will bind but not dephosphorylate PTPRK substrates.
Previously we have identified specific p120 Cat pTyr residues (Y228, Y904) which are dephosphorylated by PTPRK and PTPRM D1 domains, and are hyperphosphorylated in PTPRK-KO cells (3) . We confirmed by in lysate dephosphorylation assays that while all PTPRK-D1 containing chimeras show dephosphorylation of pY228 and pY904, PTPRU-D1 cannot dephosphorylate these p120 Cat sites ( Fig. 5D and 5E ). To investigate the cellular consequence of PTPRU binding to PTPRK substrates, we generated CRISPR-Cas9 mediated PTPRU-KO MCF10A cells. As expected, we were able to observe hyperphosphorylation of p120 Cat -pY228 and -pY904 in PTPRK-KO cells vs WT ( Fig. 5F) . Strikingly, deleting PTPRU resulted in hypophosphorylation of both p120 Cat -pY228 and -pY904 vs WT levels ( Fig. 5F and   Fig. 5G ). Taking our interaction and dephosphorylation data together, this supports a mechanism in which PTPRU can bind substrates and protect them from dephosphorylation by related phosphatases.
DISCUSSION
The receptor PTPRU exhibits divergent sequences in key catalytic motifs including a highly divergent pTyr recognition loop sequence, a unique Thr within the PTP loop and a Glu substitution in the WPD loop. Here we show that PTPRU does not possess detectable phosphatase activity against a range of substrates or in dephosphorylation assays with cell lysates. Our structural data identify multiple features that would disrupt both substrate binding and catalytic activity. Despite its inactivity, we demonstrate that PTPRU can bind to key proteins previously reported as substrates for its catalytically active paralog PTPRK. This supports a role for PTPRU as a scaffold that competes with active phosphatases at the plasma membrane to locally influence tyrosine phosphorylation dynamics and potentially cell-cell adhesion.
Previous studies have shown that WPD to WPE mutations in several active phosphatases results in significant reduction in enzyme activity (13, 36) . We show a similar substantial decrease in PTPRK activity following the introduction of the WPE sequence change. However, mutation of the PTPRU WPE loop to the canonical sequence was not sufficient to rescue any detectable phosphatase activity. Our structure of the PTPRU-D1 reveals that there are two key structural changes within this domain that alter the substrate binding pocket and therefore are likely to explain the lack of phosphatase activity. The first is the disordered pTyr recognition loop. The absence of electron density for this loop was unexpected as, although the PTPRU sequence is highly divergent, it does retain a conserved arginine (R918) that in related structures binds back into the main PTP fold and interacts with residues that are conserved in PTPRU-D1. Not only does loss of this ordered loop drastically alter the shape of the substrate binding pocket, it also contributes to decreased protein stability as demonstrated by the increased susceptibility of PTPRU to proteolysis and its lower melting temperature relative to PTPRK-D1. The second key structural change in PTPRU-D1 relates to the catalytic PTP loop, which has undergone a substantial rearrangement resulting in the occlusion of the substrate binding site, blocking the catalytic cysteine. Interestingly, the introduction of a Thr into the equivalent position of PTPRK-D1 does not reduce the phosphatase activity of this domain and mutation of the PTPRU Thr to Ala does not induce detectable PTPRU activity. Furthermore, the introduction of two mutations, T1089A and E1053D, into the PTPRU-D1 PTP and WPD loops, respectively, were still unable to rescue any activity. This combination of biochemical and structural analysis demonstrates that there are multiple mechanisms contributing to the absence of phosphatase activity in PTPRU-D1.
An intriguing feature of the inactive D2 pseudophosphatase domains in the RPTP family is the retention of the catalytic cysteine residue. The conservation of this residue in inactive domains raises the question of whether it plays an alternative, non-catalytic role in these domains. Our structure of oxidized PTPRU-D1 demonstrates that this cysteine has the capacity to form a "backdoor" disulfide similar to that seen in SHP2, LYP and PTEN phosphatases. In these enzymes, the formation of a disulfide bond has been attributed to the need to protect the catalytic cysteine from irreversible oxidative damage or to allow reversible redox-sensitive inactivation. Our observation here of a similar intramolecular disulfide in an inactive pseudophosphatase domain suggests that the proposed roles for the disulfide formation may extend beyond the modulation of enzyme activity. Indeed, previous studies on the PTPRA D2 domain suggest oxidation can promote an intermolecular disulfide bond (17), or a conformational change that is translated to the extracellular domain (43).
In addition to promoting a "backdoor" disulfide, PTP oxidation can induce chemical modification of the catalytic cysteine. One such modification is the formation of a sulfenylamide intermediate, as demonstrated for PTP1B (44, 45) . This modification involves the sidechain of the catalytic cysteine forming a covalent link to the backbone nitrogen of an adjacent residue, resulting in a substantial change to the conformation of the catalytic PTP loop. Interestingly, this loop conformation is highly similar to that seen in PTPRU-D1. In PTP1B this renders the enzyme inactive but is reversible upon reduction and is proposed to be a protective intermediate during redox-regulated inhibition. This conformation of the PTPRU-D1 PTP loop is not induced by oxidation, it is instead present in the reduced form rendering the enzyme unable to bind phosphotyrosine. This suggests PTPRU has evolved to adopt an inactive conformation, even under reducing conditions. The ICDs of other members of the R2B family comprise an active membrane-proximal D1 domain and an inactive membrane-distal D2 domain. Despite the sequence divergence of PTPRU-D1 from its paralogs (SI Appendix, Fig. S1 ) and its lack of catalytic activity, this domain still possesses higher sequence identity to D1 domains than to D2 domains (69% sequence identity with R2B family D1 domains, 28% identity with R2B family D2 domains; SI Appendix, Table S2 ). Therefore, rather than PTPRU possessing two inactive D2 domains, it retains a bona-fide D1 and D2 domain topology similar to that of related enzymes but with a D1 domain that has diverged to be catalytically inactive. By using chimeric ICDs containing D1 and D2 domains from PTPRU, PTPRK and PTPRM in cell-based dephosphorylation assays we show that the D2 domain of PTPRU can recruit substrates for dephosphorylation by the active D1 domain of PTPRK. This ability to bind substrates that overlap with active phosphatases, combined with the lack of phosphatase activity of PTPRU suggests that the likely role of PTPRU in cells is to act as a decoy receptor that sequesters substrates protecting them from dephosphorylation. In support of this, we find that genetic deletion of PTPRU leads to a reduction in phosphorylation levels of p120 Cat . In this way, PTPRU may modify cell signaling by altering the rate or extent of tyrosine dephosphorylation by related, active RPTP family members. The absence of enzyme activity demonstrated here for PTPRU does not diminish its importance but highlights a new pseudophosphatase function in cell signaling.
MATERIALS AND METHODS

Protein Expression and Purification
Constructs for expressing PTPRU, PTPRK D1 and D2 domains and chimeric intracellular domains (ICDs) were cloned with an N-terminal 6xHis-tag alone or with a tandem N-terminal 6xHis and Avi-tags. Point mutations were introduced using site-directed mutagenesis and sequence verified. All proteins were expressed in E. coli BL21 (DE3) Rosetta cells and purified using nickel-affinity and size exclusion chromatography.
Crystallization, Data Collection and Structure Determination
For crystallization trials, PTPRU-D1 protein was further purified by anion exchange chromatography and concentrated to 9.6 mg/ml in 50 mM Tris-HCl, pH 8, 300 mM NaCl, 5% glycerol, 5 mM DTT. Crystals were grown by sitting-drop vapor diffusion against a reservoir of 0.1 M Bicine, pH 9, 1 M lithium chloride, 20% (w/v) polyethylene glycol 6000. Crystals were cryoprotected in reservoir solution supplemented with 20% (v/v) glycerol and flash-cooled by plunging into liquid nitrogen. Diffraction data were collected at the Diamond Light Source (DLS) beamlines I03 and I04 and processed using the automated data processing pipelines at DLS (46) ( Table 1 ). The structure of PTPRU-D1 was solved by molecular replacement with PTPRK-D1 (PDB ID: 2C7S), model building was carried out using COOT (47) and refined using phenix.refine ( 
MATERIALS AND METHODS
Plasmids and constructs
Amino acid (aa) numbering used throughout is based on the following sequences; PTPRU; UniProt ID: Mouse anti-PTPRM (PTPRU cross-reactive; Cat#sc-56959) (2) primary antibody was purchased from Santa Cruz. Rabbit anti-PTPRK primary antibody was generated in a previous study (1) . Mouse antialpha-tubulin primary antibody was purchased from Sigma Aldrich (Cat#T6199). HRP conjugated antimouse (Cat#711-035-151) and anti-rabbit (Cat#711-035-152) secondary antibodies (1:5000 in TBS-T)
were purchased from Jackson Immuno-Research. 
Protein expression and purification
X-ray data collection and structure solution
X-ray diffraction data were recorded at Diamond Light Source (DLS) beamlines I03 and I04. Datasets were collected at λ = 0.9795 Å. Diffraction datasets were indexed and integrated using the automated data processing pipeline available at DLS, implementing XIA2 DIALS for the reduced dataset and XIA2 3dii for the oxidized dataset (3) then scaled and merged using AIMLESS (4). Resolution cut-off was determined by CC1/2 > 0.5 and I/σl > 1.5. The initial structure was solved by molecular replacement using Phaser (5) , with human PTPRK-D1 (6) (PDB ID: 2C7S) as a search model. Further refinements were performed using COOT (7) and phenix.refine (8) . Graphical figures of the PTPRU-D1 structure were rendered in PyMOL (Schrödinger, LLC). 
Phosphoinositide phosphatase activity assay
The commercially available Enzchek phosphate assay kit (Thermo Fisher Scientific) was used to measure the release of phosphate from the phosphoinositides lipids PI(4,5)P2 and PI ( 
Cells and cell culture
MCF10A cells were obtained from the American Type Culture Collection (ATCC). MCF10A cells were cultured in a previously described MCF10A growth medium (9) consisting of 1:1 DMEM:Ham's F12 supplemented with 5% (v/v) horse serum, 0.5 mg/ml hydrocortisone, 20 ng/ml EGF, 100 ng/ml cholera toxin and 10 mg/ml insulin. Cells were cultured at 37°C in a humidified 5% CO2 atmosphere in 75 cm 2 vented flasks.
Preparation of sodium pervanadate
To create a 50 mM pervanadate stock solution, 30% H2O2 was first diluted to 0.3% H2O2 in 20 mM HEPES, pH 7.3. 50 μl dilute H2O2 added to 490 μl 100 mM sodium orthovanadate (Alfa Aesar) and 450 μl H2O, then mixed by gentle inversion and incubated at RT for 5 min. After incubation, excess H2O2 was quenched by the addition of a small amount of catalase (using 200 μl pipette tip) and mixed by gentle inversion. Pervanadate was freshly prepared and used immediately to avoid decomposition. 
Generation of pervanadate-treated lysates
Reversible oxidation of recombinant protein
All steps were performed on ice unless otherwise stated. 10 μg of recombinant protein was mixed with either 0, 0.25, 1 or 2 mM H2O2 in a total reaction volume of 50 μl in ice-cold oxidation buffer (50 mM 
